FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2022
Back to search
Official data from USPTO
ADAPTIMMUNE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
08/01/2022
Classification
Registered
Trademark type
Combined
Nice classes
5, 44
Filing date
03/31/2021
Registration date
01/25/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
01/25/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
DEAN, JULES J.
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized circular design consisting of several curved parallel lines to the left of the stylized wording "ADAPTIMMUNE".
Holders and representatives
Holders
Adaptimmune Limited
Representatives
Christiane Campbell DUANE MORRIS LLP
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancer and autoimmune diseases; pharmaceutical immunotherapy preparations for use in cancer treatment; T-cell receptorspharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment
Class 44
Medical treatment services; medical immunotherapy services; medical treatment services and medical treatment services for immune-therapy comprising harvesting a patient's white blood cellscombining white blood cells with an engineered T-cell receptor therapeutictransducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient
Publications
History of USPTO decisions and trademark events.
21 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/08/2022
FIMP
FINAL DISPOSITION PROCESSED
07/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/25/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/09/2021
PUBO
PUBLISHED FOR OPPOSITION
11/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/20/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/13/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/13/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/13/2021
RFNT
REFUSAL PROCESSED BY IB
08/15/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/27/2021
RFRR
REFUSAL PROCESSED BY MPU
07/27/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/17/2021
CNRT
NON-FINAL ACTION WRITTEN
07/16/2021
DOCK
ASSIGNED TO EXAMINER
07/16/2021
MAFR
APPLICATION FILING RECEIPT MAILED
06/16/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/10/2021
Continuous trademark protection
Get notified about every new filing that threatens ADAPTIMMUNE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.